-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Inhibrx Biosciences, Lowers Price Target to $220

Benzinga·11/16/2026 12:33:01
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Inhibrx Biosciences (NASDAQ:INBX) with a Buy and lowers the price target from $245 to $220.